BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 20674792)

  • 21. Phaeohyphomycosis in a tertiary care cancer center.
    Ben-Ami R; Lewis RE; Raad II; Kontoyiannis DP
    Clin Infect Dis; 2009 Apr; 48(8):1033-41. PubMed ID: 19267655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumonia and lung infections due to emerging and unusual fungal pathogens.
    Chen SC; Blyth CC; Sorrell TC; Slavin MA
    Semin Respir Crit Care Med; 2011 Dec; 32(6):703-16. PubMed ID: 22167398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of immunocompromised patients with evidence of an invasive mycosis.
    Walsh TJ
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.
    Husain S; Alexander BD; Munoz P; Avery RK; Houston S; Pruett T; Jacobs R; Dominguez EA; Tollemar JG; Baumgarten K; Yu CM; Wagener MM; Linden P; Kusne S; Singh N
    Clin Infect Dis; 2003 Jul; 37(2):221-9. PubMed ID: 12856215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation.
    Auberger J; Lass-Flörl C; Clausen J; Bellmann R; Buzina W; Gastl G; Nachbaur D
    Diagn Microbiol Infect Dis; 2008 Nov; 62(3):336-9. PubMed ID: 18687556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients.
    Pagano L; Akova M; Dimopoulos G; Herbrecht R; Drgona L; Blijlevens N
    J Antimicrob Chemother; 2011 Jan; 66 Suppl 1():i5-14. PubMed ID: 21177404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?
    Jantunen E; Anttila VJ; Ruutu T
    Bone Marrow Transplant; 2002 Dec; 30(12):925-9. PubMed ID: 12476286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic antifungal agents used after lung transplantation.
    Marino E; Gallagher JC
    Ann Pharmacother; 2010 Mar; 44(3):546-56. PubMed ID: 20179260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy of infections caused by dematiaceous fungi.
    Revankar SG
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):601-12. PubMed ID: 16107199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary aspergillosis: a clinical update.
    Zmeili OS; Soubani AO
    QJM; 2007 Jun; 100(6):317-34. PubMed ID: 17525130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The place for itraconazole in treatment.
    Maertens J; Boogaerts M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug resistance in the treatment of invasive fungal infections].
    Nordøy I; Gaustad P
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.
    Sun HY; Singh N
    Int J Antimicrob Agents; 2010 Mar; 35(3):211-8. PubMed ID: 20036518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility testing in fungi: a global perspective on a variety of methods.
    Lass-Flörl C; Perkhofer S; Mayr A
    Mycoses; 2010 Jan; 53(1):1-11. PubMed ID: 20078786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices.
    Singh N
    Clin Infect Dis; 2001 Nov; 33(10):1692-6. PubMed ID: 11641825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aspergillosis in pulmonary transplantation].
    de Pablo A; Ussetti P; Cruz Carreño M; Lázaro T; Ferreiro MJ; López A; Mendaza P; Estada J
    Enferm Infecc Microbiol Clin; 2000 May; 18(5):209-14. PubMed ID: 10974763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of fungal infections in the immunocompromised host.
    Mahfouz T; Anaissie E
    Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fungal infections in transplantation patients].
    Colomba C; Antinori S
    Recenti Prog Med; 2003 Nov; 94(11):516-28. PubMed ID: 14679922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.